Live: Will Alphabet Smash Q2 Earnings Tonight After Berkshire Hathaway’s Big Bet?

Health and Healthcare

Amgen : AMGN

All Amgen Articles

708 Articles

Douglas A. McIntyre | Jul 23, 2009 at 9:12 AM EDT

Bristol-Myers Gets Key Assets With A Medarex Deal (BMY, MEDX, ABT, JNJ, AMGN, WYE)

Bristol Myers Inc. (NYSE: BMY) plans to spend $2.4 billion to buy partner Medarex Inc. (Nasdaq: MEDX). It will get…

Douglas A. McIntyre | Jul 22, 2009 at 4:01 AM EDT

The Next Blockbuster Drugs: A $170 Billion Opportunity

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line…

Douglas A. McIntyre | Jul 8, 2009 at 9:47 AM EDT

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

These are some of the top stories affecting key drug and biotech stocks that are covered with more in-depth details…

Douglas A. McIntyre | Jul 8, 2009 at 8:10 AM EDT

Day Trader Alerts (AMGN, NVS, MSCS, DRYS, ARYX, XNPT, ARNA, BPZ)

These are some of the top stocks for day traders and active traders to watch based on pre-market and after-hours…

Douglas A. McIntyre | Jun 25, 2009 at 11:31 AM EDT

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early…

Douglas A. McIntyre | May 27, 2009 at 1:34 PM EDT

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data…

Douglas A. McIntyre | May 6, 2009 at 6:26 AM EDT

Top Analyst Upgrades (ALU, AMGN, HBC, IFX, SMTC, DIS, WBMD)

These are some of the top pre-market analyst upgrades and positive research calls we have seen from Wall Street this…

Douglas A. McIntyre | Apr 24, 2009 at 6:30 AM EDT

Top Analyst Upgrades & Downgrades (AMGN, CS, BEAT, DV, MAR, MSFT, RIMM, SPWRA, TOL)

These are among the top research calls and analyst upgrades and downgrades we have seen early this Friday morning with…

Douglas A. McIntyre | Apr 23, 2009 at 3:27 PM EDT

Amgen Back To Doldrums (AMGN)

Amgen Inc. (NASDAQ: AMGN) has posted some very highly anticipated and uninteresting earnings. The biotech giant reported $0.98 EPS net…

Douglas A. McIntyre | Apr 17, 2009 at 2:05 PM EDT

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks. The American Association…

Douglas A. McIntyre | Mar 27, 2009 at 6:59 AM EDT

Top 10 Analyst Upgrades & Downgrades (AMGN, COP, DD, GENZ, GS, MON, MOS, BBY, PBR, VMW)

These are ten of the top impact research calls with upgrades and downgrades from Wall Street early this Friday morning:…

Douglas A. McIntyre | Feb 20, 2009 at 5:08 AM EST

Ten Large American Companies That Won’t Cut Jobs

Layoffs at big companies are so common now that it is novel when a day goes by without Microsoft (MSFT),…

Douglas A. McIntyre | Feb 5, 2009 at 5:57 PM EST

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Biogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning. What many investors probably want to know…

Douglas A. McIntyre | Jan 5, 2009 at 7:15 AM EST

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT…

Douglas A. McIntyre | Dec 10, 2008 at 11:04 AM EST

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally…

1 … 41 42 43 44 45 … 48

Amgen : AMGN

All Amgen Articles

Bristol-Myers Gets Key Assets With A Medarex Deal (BMY, MEDX, ABT, JNJ, AMGN, WYE)

The Next Blockbuster Drugs: A $170 Billion Opportunity

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

Day Trader Alerts (AMGN, NVS, MSCS, DRYS, ARYX, XNPT, ARNA, BPZ)

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

Top Analyst Upgrades (ALU, AMGN, HBC, IFX, SMTC, DIS, WBMD)

Top Analyst Upgrades & Downgrades (AMGN, CS, BEAT, DV, MAR, MSFT, RIMM, SPWRA, TOL)

Amgen Back To Doldrums (AMGN)

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

Top 10 Analyst Upgrades & Downgrades (AMGN, COP, DD, GENZ, GS, MON, MOS, BBY, PBR, VMW)

Ten Large American Companies That Won’t Cut Jobs

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

Live: Will Alphabet Smash Q2 Earnings Tonight After Berkshire Hathaway’s Big Bet?

Live: Will Tesla Crush Tonight’s Q2 Earnings After Big Delivery Volume Beat?

Live: Will ServiceNow’s Q2 Earnings Tonight Drive a Rebound After 38% YTD Decline?

DVY’s 3.3% Yield Looks Weak Against 4.55% Treasury Rates Right Now

Direxion Enters SK Hynix Space With SKHL, a High-Risk 2X Leveraged Fund

Why Your Nest Egg Size Does Not Matter (But This One Number Does)

She Divorced at 66 and Her Income Never Changed. Her Medicare Bracket Did.

A $1 Million 401(k) Is Really Worth About $760,000 After Taxes. Here's the Math Retirees Miss.

DVY’s 3.3% Yield Looks Weak Against 4.55% Treasury Rates Right Now

Direxion Enters SK Hynix Space With SKHL, a High-Risk 2X Leveraged Fund

Amgen : AMGN

All Amgen Articles

Bristol-Myers Gets Key Assets With A Medarex Deal (BMY, MEDX, ABT, JNJ, AMGN, WYE)

The Next Blockbuster Drugs: A $170 Billion Opportunity

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

Day Trader Alerts (AMGN, NVS, MSCS, DRYS, ARYX, XNPT, ARNA, BPZ)

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

Top Analyst Upgrades (ALU, AMGN, HBC, IFX, SMTC, DIS, WBMD)

Top Analyst Upgrades & Downgrades (AMGN, CS, BEAT, DV, MAR, MSFT, RIMM, SPWRA, TOL)

Amgen Back To Doldrums (AMGN)

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

Top 10 Analyst Upgrades & Downgrades (AMGN, COP, DD, GENZ, GS, MON, MOS, BBY, PBR, VMW)

Ten Large American Companies That Won’t Cut Jobs

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

Live: Will Alphabet Smash Q2 Earnings Tonight After Berkshire Hathaway’s Big Bet?

Live: Will Tesla Crush Tonight’s Q2 Earnings After Big Delivery Volume Beat?

Live: Will ServiceNow’s Q2 Earnings Tonight Drive a Rebound After 38% YTD Decline?

DVY’s 3.3% Yield Looks Weak Against 4.55% Treasury Rates Right Now

Direxion Enters SK Hynix Space With SKHL, a High-Risk 2X Leveraged Fund

Why Your Nest Egg Size Does Not Matter (But This One Number Does)

Featured Reads

She Divorced at 66 and Her Income Never Changed. Her Medicare Bracket Did.

A $1 Million 401(k) Is Really Worth About $760,000 After Taxes. Here's the Math Retirees Miss.